Prof. Jan G. J. van de Winkel, Ph.D., was President and Chief Executive Officer of Genmab A/S since 2010. He is Cofounder of the Company and has previously served as its President, Research & Development and Chief Scientific Officer. Earlier in his carrier, he worked as Vice President and Scientific Director of Medarex Europe. Prof. van de Winkel holds a professorship in Immunotherapy at Utrecht University and is Member of the Scientific Advisory Boards of Thuja Capital Healthcare Fund and the Advisory Board of Capricorn Healthtech Fund. Additionally, he chairs the Board of Regenesance and serves as Member on the Boards of Directors of ISA Pharmaceuticals and Celdara Medical. Prof. van de Winkel holds MS and Doctorate of Philosophy degrees from the University of Nijmegen.
van de Winkel holds a professorship in Immunotherapy at Utrecht University and is Member of the Scientific Advisory Boards of Thuja Capital Healthcare Fund and the Advisory Board of Capricorn Healthtech Fund. Additionally, he is Member of the Board of Directors of ISA Pharmaceuticals and Chairman of the Board of Directors of Regenesance. He holds MS and Doctorate of Philosophy degrees from the University of Nijmegen.
Click "OK" to permanently delete this portfolio. Click "Cancel" if you have changed your mind.
Report was successfully generated
You can either (1) right-mouth click the image to download it to your local drive or simply (2) copy and paste the
image data below to include picture of this graph on your web page without downloading the image file
Copy and paste above text right to your web page html
Macroaxis is user-driven community of investors. We appreciate any feedback or comment you can provide.
Please fill out our quick survey to help us provide your with a better service and user experience
Most of the functionality on our site is free to use.
However we do provide premium service to sophisticated investors. Our premium subscription will give you unprecedented
capabilities to optimize your portfolios using robust financial analysis toolkit, fast mean-variance optimization engine, and proven portfolio theory
OTC GNMSY
-0.26% 
Equity Search
Advanced Search
Market Screener
Adviser Directory
Suggest Portfolio
Backtest Watchlist
Analyze Correlations
View Transactions
Check Volatility
Import Equities
Copenhagen
